摘要
作者观察了６０例患者服用甲孕酮后改善化疗所致的厌食、体重下降及骨髓抑制作用，并进行对比研究。全部患者随机分成Ａ、Ｂ、Ｃ三组，Ａ组第１周期接受化疗＋甲孕酮，第２、３周期单用化疗；Ｂ组第１周期单用化疗，第２周期化疗＋甲孕酮，第３周期单用化疗；Ｃ组３个周期均化疗＋甲孕酮。结果表明，三组患者在化疗＋甲孕酮治疗的周期中均有较明显的进食量增加及体重增长，其中Ａ组８５％的患者体重增加，平均增加２．５ｋｓ（１～７ｋｇ）；Ｂ组８０％体重增加，平均增长２．２５ｋｇ（１．５～５ｋｇ）；Ｃ组９５％体重增加，平均增加４ｋｇ（２．５～８ｋｇ）。另外，骨髓抑制按世界卫生组织（ＷＨＯ）抗癌药急性毒性分级标准Ⅲ度以上者在单化疗的８０个周期中，有４２个周期（５２．５％）；而化疗加甲孕酮组１００个周期中，骨髓抑制仅有１９个周期（１９．０％）。两组差异有显著性意义（Ｐ＜０．０１）。
Abstract From October,1993 to September,1994 a controlled
clinical trial was conducted in 60 patientson Furlutal in the
prevention of anorexia , weight loss and myelosuppression caused by
Chemotherapy.Patients were randomly divieded into three groups, they
received Furlutal in the lst(group A) , 2nd(group B)and every cycle
in(group c),respectively. The results show that Furlutal is effective
inpreventinganorexia , weight loss and myelosuppression, In group A ,
85%patients gained weigh,averaged 2.5kg(range: 1～7kg) ; 80%in group
B,averged 2.25ks(1～7kg) and 95%in group C,averaged 4kg(2.5～8kg).
Grade Ⅲ myelosuppression , according to WHO criteria,
52.5%occurredin of patients treated with 80 cycles of chemotherapy
only while it occurred in 19%in those treatedwith 100 cycles of
chemotherapy plus Furlutal (P<0.01).
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
1995年第4期283-285,共3页
Chinese Journal of Oncology
